-
Beaten-Down Bitoech: Gilead And Bristol-Myers Squibb
Post on 4/11/17
-
Should I Buy Amgen Or Pfizer?
Post on 4/11/17
-
Q Biomed Completes Final Closing On $4,000,000 Funding
Post on 4/10/17
-
3 Big Pharma Companies With the Best Pipelines
Post on 4/10/17
-
Why Verizon Communications Inc. Shareholders Have Something to Worry About
Post on 4/6/17
-
The 3 Most Important Numbers for Pfizer Inc.
Post on 4/6/17
-
Meadowlands Veterinary Hospital Opens State of the Art Facility
Post on 4/5/17
-
Here's Why The Best Is Yet to Come for Johnson & Johnson
Post on 4/5/17
-
Karyopharm and Medidata Expand Clinical Trial Partnership
Post on 4/4/17
-
Tonix Pharmaceuticals Completes $8 Million Public Offering of Common Stock
Post on 4/4/17
-
Johnson & Johnson: Selling And Still Getting Richer
Post on 4/4/17
-
Caladrius Biosciences Adds Four Clinical Sites, Including Joslin Diabetes Center
Post on 4/3/17
-
Cara Therapeutics Is Scratching the Itch for Promising Biotechs
Post on 4/3/17
-
Could Pfizer Buy Esperion Therapeutics?
Post on 4/3/17
-
Here's How Much Johnson & Johnson Will Probably Raise Its Dividend Next Month
Post on 4/3/17
-
3 Big Healthcare Stocks That Wall Street Predicts Will Grow the Fastest
Post on 4/3/17
-
CytoSorbents Announces Pricing of Follow-On Offering
Post on 4/2/17
-
Johnson & Johnson: The Senate Probe And Other Risks
Post on 3/31/17
-
Regeneron's Game-Changing New Eczema Drug Could Be a Blockbuster
Post on 3/31/17
-
Should Investors Worry About Bristol-Myers Squibb's Recent Setbacks?
Post on 3/31/17
-
Cara Therapeutics Announces Pricing of Its Public Offering of Common Stock
Post on 3/31/17
-
Akers Biosciences Announces a $2 Million Private Placement
Post on 3/31/17
-
CytoSorbents Announces Proposed Offering of Common Stock
Post on 3/30/17
-
Worried About Johnson & Johnson's Valuation? Consider This Crazy, Undervalued, 4.2% Yielding Pharmaceutical Stock Instead
Post on 3/30/17
-
BioDigital Collaborates with Johns Hopkins Medicine
Post on 3/29/17
New York
